Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Berger

Showing results (31-40 of 63) with videos related to

Pageof 7
Sort By:
Methods in Molecular Medicine|March 29, 2002
Murine models of CF airway infection and inflammationJames F Chmiel, Michael W Konstan, Melvin Berger
Clinical Immunology (Orlando, Fla.)|March 1, 2011
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficienciesMelvin Berger, Mikhail Rojavin, Peter Kiessling, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2002
Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantationDenise R Sokos, Melvin Berger, Hillard M Lazarus
Southern Medical Journal|August 7, 2010
Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin GMelvin Berger, Elyse Murphy, Patty Riley, et al.
Journal of the Peripheral Nervous System : JPNS|November 9, 2013
Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesMelvin Berger, Daniel E McCallus, Cindy Shin-Yi Lin
Journal of Inflammation (London, England)|October 14, 2011
Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cellsAicha Saadane, Jean Eastman, Melvin Berger, et al.
Immunotherapy|May 17, 2018
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>®</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgGMelvin Berger, Thomas Harbo, David R Cornblath, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
A pilot study of equal doses of 10% IGIV given intravenously or subcutaneouslyShilpa H Desai, Akhil Chouksey, John Poll, et al.
Postgraduate Medicine|September 10, 2011
Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseasesMark R Stein, Alan Koterba, Linda Rodden, et al.
Blood Reviews|September 30, 2017
Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantationMasumi Ueda, Melvin Berger, Robert Peter Gale, et al.
Pageof 7

Showing results (31-40 of 63) with videos related to

Sort By:
Pageof 7
Methods in Molecular Medicine|March 29, 2002
Murine models of CF airway infection and inflammationJames F Chmiel, Michael W Konstan, Melvin Berger
Clinical Immunology (Orlando, Fla.)|March 1, 2011
Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficienciesMelvin Berger, Mikhail Rojavin, Peter Kiessling, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2002
Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantationDenise R Sokos, Melvin Berger, Hillard M Lazarus
Southern Medical Journal|August 7, 2010
Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin GMelvin Berger, Elyse Murphy, Patty Riley, et al.
Journal of the Peripheral Nervous System : JPNS|November 9, 2013
Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodiesMelvin Berger, Daniel E McCallus, Cindy Shin-Yi Lin
Journal of Inflammation (London, England)|October 14, 2011
Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cellsAicha Saadane, Jean Eastman, Melvin Berger, et al.
Immunotherapy|May 17, 2018
IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>®</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgGMelvin Berger, Thomas Harbo, David R Cornblath, et al.
The Journal of Allergy and Clinical Immunology|September 22, 2009
A pilot study of equal doses of 10% IGIV given intravenously or subcutaneouslyShilpa H Desai, Akhil Chouksey, John Poll, et al.
Postgraduate Medicine|September 10, 2011
Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseasesMark R Stein, Alan Koterba, Linda Rodden, et al.
Blood Reviews|September 30, 2017
Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantationMasumi Ueda, Melvin Berger, Robert Peter Gale, et al.
Pageof 7